Trade Names:Clarinex- Syrup 2.5 mg per 5 mL- Tablets 5 mg
Trade Names:Clarinex Reditabs- Tablets, rapidly disintegrating 2.5 mg- Tablets, rapidly disintegrating 5 mgAerius (Canada)Aerius Kids (Canada)
Long-acting histamine antagonist with selective H 1 -receptor histamine antagonist activity.
T max is approximately 3 h. C max is approximately 4 ng/mL. AUC is approximately 56.9 ng•h/mL.
82% to 87% protein bound.
Metabolized to 3-hydroxydesloratadine (active).
The half-life is 27 h. Approximately 87% is excreted in urine and feces.
AUC and C max are increased. Dosage adjustment is recommended.Hepatic Function Impairment
AUC and half-life are increased. Dosage adjustment is recommended.Elderly
C max and AUC are 20% higher. The half-life is 33.7 h.Children
Desloratadine plasma concentrations are similar to those achieved in adults.
Relief of nasal and nonnasal symptoms of seasonal and perennial allergic rhinitis; relief of symptoms of pruritus and reduction in number and size of hives in chronic idiopathic urticaria.
Hypersensitivity to any components of the product or to loratadine.
PO 5 mg once daily.Children 6 to 11 yr of age
PO 2.5 mg once daily.Children 12 mo to 5 yr of age
PO 1.25 mg once daily.Children 6 to 11 mo of age
PO 1 mg once daily.Renal/Hepatic Impairment Adults
PO 5 mg every other day.
Advise patients to take with or without food.
Administer syrup with a commercially available measuring dropper or syringe that is calibrated.
Administer orally disintegrating tablets with or without water. Place on tongue and allow to disintegrate before swallowing. Tablet should be taken immediately after opening the blister.
The use of orally disintegrating tablets is for patients 6 yr of age and older.
Store at 59° to 86°F. Do not remove orally disintegrating tablet from blister until just prior to administration.
None well documented.
May prevent or diminish otherwise positive reactions to skin tests.
Palpitations, tachycardia (postmarketing).
Headache (14%); irritability (12%); somnolence (9%); fatigue, insomnia (5%); dizziness (4%); emotional liability (3%); psychomotor hyperactivity, seizure (postmarketing).
Erythema, maculopapular rash (3%).
Otitis media (6%); pharyngitis, rhinorrhea (5%); dry mouth, epistaxis (3%).
Diarrhea (20%); vomiting (6%); anorexia, nausea (5%); appetite increased, dyspepsia (3%).
UTI (4%); dysmenorrhea (2%).
Elevated liver enzymes, including bilirubin, and, very rarely, hepatitis (postmarketing).
Upper respiratory tract infection (21%); cough (11%); bronchitis (6%).
Fever (17%); varicella (4%); myalgia, parasitic infection (3%); hypersensitivity, including anaphylaxis, dyspnea, edema, pruritus, rash, urticaria (postmarketing).
Assess patient for allergy symptoms (eg, hives, itching, nasal congestion, rhinitis, sneezing, watery eyes) before starting therapy and periodically throughout therapy. Monitor patient for dizziness and excessive drowsiness. If noted, hold therapy.
Category C .
Excreted in breast milk.
Safety and efficacy not established in children younger than 6 mo of age (tablets and syrup). Desloratadine orally disintegrating tablets are intended for children 6 yr of age and older.
Select dose with caution, reflecting greater frequency of decreased hepatic, renal, or cardiac function, and comorbidity.
Dosage adjustment is recommended.
Dosage adjustment is recommended.
Orally disintegrating tablets contain phenylalanine 2.9 mg per 5 mg tablet or 1.4 mg per 2.5 mg tablet.
Increased heart rate and QT interval; somnolence.
Copyright © 2009 Wolters Kluwer Health.